These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26056464)

  • 21. Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release.
    Gobira PH; Vilela LR; Gonçalves BD; Santos RP; de Oliveira AC; Vieira LB; Aguiar DC; Crippa JA; Moreira FA
    Neurotoxicology; 2015 Sep; 50():116-21. PubMed ID: 26283212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
    Zlebnik NE; Cheer JF
    Annu Rev Neurosci; 2016 Jul; 39():1-17. PubMed ID: 27023732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
    Qian Y; Gurley BJ; Markowitz JS
    J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors.
    Hartmann A; Lisboa SF; Sonego AB; Coutinho D; Gomes FV; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109637. PubMed ID: 31054943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders.
    Scuderi C; Filippis DD; Iuvone T; Blasio A; Steardo A; Esposito G
    Phytother Res; 2009 May; 23(5):597-602. PubMed ID: 18844286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Cannabidiol on Psychiatric and Medical Conditions.
    Oberbarnscheidt T; Miller NS
    J Clin Med Res; 2020 Jul; 12(7):393-403. PubMed ID: 32655732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Meta-Review of Impulsivity and Compulsivity in Addictive Behaviors.
    Lee RSC; Hoppenbrouwers S; Franken I
    Neuropsychol Rev; 2019 Mar; 29(1):14-26. PubMed ID: 30927147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is there a role for cannabidiol in psychiatry?
    Khoury JM; Neves MCLD; Roque MAV; Queiroz DAB; Corrêa de Freitas AA; de Fátima Â; Moreira FA; Garcia FD
    World J Biol Psychiatry; 2019 Feb; 20(2):101-116. PubMed ID: 28112021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual Reality (VR) in Assessment and Treatment of Addictive Disorders: A Systematic Review.
    Segawa T; Baudry T; Bourla A; Blanc JV; Peretti CS; Mouchabac S; Ferreri F
    Front Neurosci; 2019; 13():1409. PubMed ID: 31998066
    [No Abstract]   [Full Text] [Related]  

  • 31. The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.
    Batalla A; Janssen H; Gangadin SS; Bossong MG
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review.
    Patel S; Khan S; M S; Hamid P
    Cureus; 2020 Jul; 12(7):e9309. PubMed ID: 32839678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
    Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
    Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabis abuse and addiction: a contemporary literature review.
    Iyalomhe GB
    Niger J Med; 2009; 18(2):128-33. PubMed ID: 19630315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: mini review.
    Yamada K; Nabeshima T
    Ann N Y Acad Sci; 2004 Oct; 1025():198-204. PubMed ID: 15542718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Cannabidiol a Promising Substance for New Drug Development? A Review of its Potential Therapeutic Applications.
    Noreen N; Muhammad F; Akhtar B; Azam F; Anwar MI
    Crit Rev Eukaryot Gene Expr; 2018; 28(1):73-86. PubMed ID: 29773016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway.
    Renard J; Loureiro M; Rosen LG; Zunder J; de Oliveira C; Schmid S; Rushlow WJ; Laviolette SR
    J Neurosci; 2016 May; 36(18):5160-9. PubMed ID: 27147666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.